For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $6.31 in the prior trading day, Mimedx Group Inc (NASDAQ: MDXG) closed at $6.1, down -3.33%. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 1.1 million shares were traded. MDXG stock price reached its highest trading level at $6.35 during the session, while it also had its lowest trading level at $6.04.
Ratios:
Our goal is to gain a better understanding of MDXG by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.76. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.41. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on July 02, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.
On March 07, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12.
On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.Craig Hallum initiated its Buy rating on October 27, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 06 ’25 when Maersk-Moller Kimberly sold 58,300 shares for $7.42 per share. The transaction valued at 432,329 led to the insider holds 236,982 shares of the business.
Kimberly Ann Maersk-Moller bought 68,587 shares of MDXG for $502,743 on Nov 06 ’25. On May 02 ’25, another insider, Capper Joseph H, who serves as the Chief Executive Officer of the company, bought 200,000 shares for $6.34 each. As a result, the insider paid 1,268,000 and bolstered with 529,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 903423168 and an Enterprise Value of 779554176. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.34, and their Forward P/E ratio for the next fiscal year is 17.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.38 while its Price-to-Book (P/B) ratio in mrq is 3.78. Its current Enterprise Value per Revenue stands at 1.981 whereas that against EBITDA is 11.362.
Stock Price History:
The Beta on a monthly basis for MDXG is 1.59, which has changed by -0.2873832 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, MDXG has reached a high of $9.36, while it has fallen to a 52-week low of $5.79. The 50-Day Moving Average of the stock is -12.96%, while the 200-Day Moving Average is calculated to be -11.23%.
Shares Statistics:
The stock has traded on average 876.11K shares per day over the past 3-months and 906740 shares per day over the last 10 days, according to various share statistics. A total of 148.08M shares are outstanding, with a floating share count of 116.72M. Insiders hold about 21.19% of the company’s shares, while institutions hold 51.90% stake in the company. Shares short for MDXG as of 1765756800 were 4599063 with a Short Ratio of 5.25, compared to 1763078400 on 4681432. Therefore, it implies a Short% of Shares Outstanding of 4599063 and a Short% of Float of 3.8900003.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.44 and $0.4 for the fiscal current year, implying an average EPS of $0.42. EPS for the following year is $0.25, with 2.0 analysts recommending between $0.29 and $0.2.
Revenue Estimates
5 analysts predict $106.93M in revenue. The current quarter. It ranges from a high estimate of $111M to a low estimate of $99.5M. As of. The current estimate, Mimedx Group Inc’s year-ago sales were $92.91MFor the next quarter, 5 analysts are estimating revenue of $95M. There is a high estimate of $102.5M for the next quarter, whereas the lowest estimate is $82M.
A total of 5 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $411.6M, while the lowest revenue estimate was $400M, resulting in an average revenue estimate of $407.48M. In the same quarter a year ago, actual revenue was $348.88MBased on 5 analysts’ estimates, the company’s revenue will be $416.08M in the next fiscal year. The high estimate is $464.9M and the low estimate is $378M.
